We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

15 hedge funds and large institutions have $9.09M invested in Bellerophon Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

12% less funds holding

Funds holding: 17 → 15 (-2)

20% less capital invested

Capital invested by funds: $11.4M → $9.09M (-$2.31M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$56K
2
LPL Financial
LPL Financial
California
+$36.1K
3
VKH
Virtu KCG Holdings
New York
+$25.8K
4
UBS Group
UBS Group
Switzerland
+$13.7K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$9.8K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$54.3K
2
BIT
BlackRock Institutional Trust
California
-$50K
3
TSS
Two Sigma Securities
New York
-$22K
4
Walleye Trading
Walleye Trading
New York
-$1K
5
TRCT
Tower Research Capital (TRC)
New York
-$48
Name Holding Trade Value Shares
Change 		Change in
Stake
NMVA
1
New Mountain Vantage Advisers
New York
$6.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.69M – – –
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$214K +$9.8K +406 +4%
LPL Financial
4
LPL Financial
California
$99K +$36.1K +1,496 +46%
Renaissance Technologies
5
Renaissance Technologies
New York
$78K +$56K +2,320 +168%
Vanguard Group
6
Vanguard Group
Pennsylvania
$75K -$54.3K -2,251 -39%
VKH
7
Virtu KCG Holdings
New York
$45K +$25.8K +1,070 +98%
Creative Planning
8
Creative Planning
Kansas
$27K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$24K +$8.18K +339 +42%
GA
10
Geneva Advisors
Illinois
$18K – – –
UBS Group
11
UBS Group
Switzerland
$13K +$13.7K +567 +1,112%
TRCT
12
Tower Research Capital (TRC)
New York
$1K -$48 -2 -4%
Morgan Stanley
13
Morgan Stanley
New York
$1K – – –
Envestnet Asset Management
14
Envestnet Asset Management
Illinois
$1K +$1.62K +67 New
BIT
15
BlackRock Institutional Trust
California
– -$50K -1,892 Closed
TSS
16
Two Sigma Securities
New York
– -$22K -858 Closed
Walleye Trading
17
Walleye Trading
New York
– -$1K -47 Closed

BLPH Hedge Fund Activity: Q3 2016 in Review

15 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2016, worth a combined $9.09M — down 20% from $11.4M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BLPH and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $56K. The largest seller was Vanguard Group, cutting an estimated $54.3K.

  • 15 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2016, down from 17 in Q2 2016.
  • Funds reported $9.09M of Bellerophon Therapeutics, Inc. stock for Q3 2016, down 20% quarter-over-quarter.
  • 1 fund opened new Bellerophon Therapeutics, Inc. positions in Q3 2016 and 3 closed out, a net change of -2 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q3 2016 was Renaissance Technologies, an estimated $56K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q3 2016 was Vanguard Group, an estimated $54.3K sold.

Based on aggregated 13F filings for Q3 2016.